Physician profile
Emmanuel Pardo
NPI 1104387331
$4,916.16
in general payments reported to CMS, 2019-2025
20 companies · $3,021 in 2025
The $3,021 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $102 · 2024: $1,793 · 2025: $3,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,591 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,591.49 |
| Education | $222.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $889.71 | 2024-2025 | |
| Amgen INC. | $724.34 | 2024-2025 | Tavneos, Evenity, Krystexxa |
| Janssen Biotech, INC. | $531.35 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $526.06 | 2024-2025 | |
| Glaxosmithkline, LLC. | $525.43 | 2024-2025 | Benlysta |
| Pfizer INC. | $287.75 | 2024-2025 | |
| Ucb, INC. | $254.93 | 2024-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $221.85 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $204.23 | 2024-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $130.04 | 2024-2025 | Orencia |
| Radius Health, INC. | $119.17 | 2024-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $87.47 | 2024-2025 | Acthar |
| Fresenius Kabi USA, LLC | $74.29 | 2024-2025 | Idacio, Tyenne |
| Aurinia Pharma U.S., INC. | $50.35 | 2025 | Lupkynis |
| Sobi, INC | $45.01 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $35.30 | 2024 | Hyrimoz |
| Genzyme Corporation | $33.00 | 2025 | |
| Almatica Pharma LLC | $27.03 | 2025 | Teriparatide |
| Gilead Sciences, INC. | $25.74 | 2025 | Biktarvy |
| Lilly USA, LLC | $20.63 | 2024 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Pardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.